Audience: CC All Location: Benefits/A-Z List System: N/A Updated: 1.18.24

Reviewed: 1.27.23

Electric Cell-Signaling Treatment

Also known as

- 1. neoGEN® System
- 2. Sanexas Intl.

Description

Electric cell-signaling treatment is the use of electronic signal energy waves produced by an ultra-high digital frequency generator. These pulsed energy waves are noninvasively delivered directly to the desired anatomical region of the body. The neoGEN-Series system is similar to a TENS unit, but it is larger in size and penetrates deeper into the tissue to purportedly more effectively reduce pain.

Prior to applying the electronic signal energy, the individual may first consider the option to receive a series of injections of a proprietary blend of vitamins. The treatment has been suggested for circulatory issues, acute or chronic pain, and various neuromuscular indications. A series of neoGEN treatments are performed (such as 6 to 15) depending on the condition being treated.

Table of Contents

The following topics are included in this document:

- Commercial
- Government Programs
- Individual and Family Business (IFB)

Document history

Date	Description
1.18.24	Updated to new template.
1.27.23	New A-Z sheet.

Commercial

Introduction

This section applies to all Commercial members. Benefit details depend on the member's brand: Dean (including Dean Health Plan (DHP) and Prevea360), Mayo Medical Plan (MMP), or Medica (including MHPS).

Dean (DHP, Prevea360)

A Medical Policy, Electric Cell-Signaling Treatment (e.g., neoGen© System, Sanexax Intl.) (MP9701), applies.

Tip: For instructions on locating policies, see **Coverage and Prior Authorization Guidelines**.

• Considered investigative, not covered.

Mayo Medical Plan (MMP)

A Coverage Policy, Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.), applies.

Tip: For instructions on locating policies, see Coverage and Prior Authorization Guidelines.

Medica (including MHPS)

A Coverage Policy, Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.), applies.

Tip: For instructions on locating policies, see <u>Coverage and Prior Authorization Guidelines</u>.

• Considered investigative, not covered.

Document history

Date	Description
1.18.24	Updated to new template.
1.27.23	New A-Z sheet.

Government Programs

Introduction

This section applies to all Medicaid and Medicare products.

AccessAbility (SNBC),

Medicaid only groups:

• Refer to Medicaid below.

Minnesota Senior Care Plus (MSC+)

Medicare eligible groups:

- Considered investigative, not covered.
- Note: If the member says this is medically necessary, offer an Organization Determination. Refer to <u>Member-Initiated PA</u>
 (<u>Organization Determination</u>) Request.
- Follows Medicare guidelines.
- Medicare is the primary payer.
- If no Medicare eligibility, Medicaid applies. Refer to Medicaid below.

AccessAbility Enhanced (I-SNBC),

A Coverage Policy, Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.), applies.

Tip: For instructions on locating policies, see <u>Coverage and Prior Authorization Guidelines</u>.

DUAL (MSHO)

- Considered investigative, not covered.
- Note: If the member says this is medically necessary, offer an Organization Determination. Refer to <u>Member-Initiated PA</u> (<u>Organization Determination</u>) Request.
- Medica is the only payer.

Cost (Prime)

Check for an LCD or NCD. If one does not exist, Medica's Coverage Policy, *Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.)*, applies.

Tip: For instructions on locating policies, see Coverage and Prior Authorization Guidelines.

- Considered investigative, not covered.
- Note: If the member says this is medically necessary, offer an Organization Determination. Refer to <u>Member-Initiated PA</u>
 (Organization Determination) Request.
- Follows Medicare guidelines.

Med Advantage

A Coverage Policy, Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.), applies.

Tip: For instructions on locating policies, see <u>Coverage and Prior Authorization Guidelines</u>.

- Considered investigative, not covered.
- Note: If the member says this is medically necessary, offer an Organization Determination. Refer to <u>Member-Initiated PA</u> (<u>Organization Determination</u>) Request.
- Follows Medicare guidelines.
- Medica is the only payer.

Med Supp (Select, Signature)

Considered investigative, not covered.

- Follows Medicare guidelines.
- Medicare supplement.
- Medicare is the primary payer.

Medicaid

A Coverage Policy, Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.), applies.

Tip: For instructions on locating policies, see Coverage and Prior Authorization Guidelines.

• Considered investigative, not covered.

Document history

Date	Description
1.18.24	Added Organization Determination note to all except Med Supp and Medicaid.
1.18.24	Updated to new template.
1.27.23	New A-Z sheet.

Individual and Family Business (IFB)

Introduction

This section applies to all Individual and Family Business (IFB) members. Benefit details depend on the member's brand: Dean (including Dean Health Plan (DHP), Medica (formerly WellFirst), and Prevea360) or Medica.

Dean (DHP, Medica formerly WellFirst, Prevea360)

A Medical Policy, Electric Cell-Signaling Treatment (e.g., neoGen© System, Sanexax Intl.) (MP9701), applies.

Tip: For instructions on locating policies, see Coverage and Prior Authorization Guidelines.

• Considered investigative, not covered.

Medica

A Coverage Policy, Electric Cell-Signaling Treatment (e.g., neoGEN® System, Sanexas Intl.), applies.

Tip: For instructions on locating policies, see <u>Coverage and Prior Authorization Guidelines</u>.

• Considered investigative, not covered.

Document history

Date	Description
1.18.24	Updated to new template.
1.27.23	New A-Z sheet.